Is Recormon less painful than Eprex after subcutaneous administration?
- PMID: 1528712
- DOI: 10.1007/BF01980483
Is Recormon less painful than Eprex after subcutaneous administration?
Abstract
In this study, we examined the differences in pain score after subcutaneous injection of the epoetin preparations Eprex and Recormon. Patients (n = 30) received 5 injections Eprex and 5 injections Recormon in a randomized double-blind sequence. 10 Min after receiving the injection the patient was asked to complete a visual and a verbal analogue scale and two descriptive scales. The results of 25 patients were used for statistical evaluation. The overall results indicate that there are significantly more patients reporting pain after subcutaneous injection of Eprex than after Recormon (11 versus 2 patients, p less than 0.05; McNemar test). 12 Patients reported no differences in pain. 43 Out of 123 injections Eprex and 69 out of 125 injections Recormon caused no pain (p less than 0.01; chi 2 9.455). For 4 patients Recormon was significantly (p less than 0.05) less painful than Eprex. It can be concluded that Recormon may be a less painful alternative for individual patients reporting pain after subcutaneous injection of Eprex.
Similar articles
-
Subcutaneous erythropoietin alpha (Eprex) is more painful than erythropoietin beta (Recormon).Nephrol Dial Transplant. 1998 Mar;13(3):817. doi: 10.1093/oxfordjournals.ndt.a027876. Nephrol Dial Transplant. 1998. PMID: 9550687 Clinical Trial. No abstract available.
-
Experience of pain after subcutaneous administration of different preparations of recombinant human erythropoietin: a randomized, double-blind crossover study.Clin Nephrol. 1991 Dec;36(6):294-8. Clin Nephrol. 1991. PMID: 1769141 Clinical Trial.
-
Pain at the injection site of subcutaneously administered erythropoietin: phosphate-buffered epoetin alpha compared to citrate-buffered epoetin alpha and epoetin beta.Clin Nephrol. 1998 Jan;49(1):41-4. Clin Nephrol. 1998. PMID: 9491285 Clinical Trial.
-
Pure red cell aplasia with anti-erythropoietin antibodies occurs more commonly with one formulation of epoetin alfa than another.Curr Med Res Opin. 2004 Jan;20(1):83-6. doi: 10.1185/030079903125002702. Curr Med Res Opin. 2004. PMID: 14741076 Review.
-
Importance of biologic follow-ons: experience with EPO.Best Pract Res Clin Haematol. 2005;18(3):381-7. doi: 10.1016/j.beha.2005.01.014. Best Pract Res Clin Haematol. 2005. PMID: 15792912 Review.
Cited by
-
Epoetin Beta: a review of its clinical use in the treatment of anaemia in patients with cancer.Drugs. 2004;64(3):323-46. doi: 10.2165/00003495-200464030-00006. Drugs. 2004. PMID: 14871172 Review.
-
Epoetin alfa. A review of its clinical efficacy in the management of anaemia associated with renal failure and chronic disease and its use in surgical patients.Drugs Aging. 1995 Aug;7(2):131-56. doi: 10.2165/00002512-199507020-00007. Drugs Aging. 1995. PMID: 7579784 Review.
-
Epoetin: a pharmacoeconomic review of its use in chronic renal failure and its effects on quality of life.Pharmacoeconomics. 1993 Jan;3(1):45-82. doi: 10.2165/00019053-199303010-00006. Pharmacoeconomics. 1993. PMID: 10146987 Review.
-
Epoetin beta. A review of its pharmacological properties and clinical use in the management of anaemia associated with chronic renal failure.Drugs. 1996 Feb;51(2):299-318. doi: 10.2165/00003495-199651020-00008. Drugs. 1996. PMID: 8808169 Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical